Product Information

RIVAROXABAN 1 MG/ML SUSPENSION is a generic product labeled by Ascend Laboratories, LLC, priced at $1.7482 per ML under NDC 67877088271. Its NADAC has been published 36 times since Dec 17, 2025.

FDA first approved this application on Jun 26, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Rivaroxaban market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

RIVAROXABAN 1 MG/ML SUSPENSION

Rivaroxaban
$1.7482per ML
High Outlier

Strength

155 mg/1

NDC

67877088271

Classification

Generic

Dosage Form

GRANULE, FOR SUSPENSION

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

RIVAROXABAN

Approval Type

Generic (ANDA)

FDA Application

ANDA218502

FDA Approved

6/26/2025

TE Code

AB

On Market Since

7/7/2025

Pharmacological Classes

Factor Xa Inhibitor
Factor Xa Inhibitors

Price Statistics

The NADAC for RIVAROXABAN 1 MG/ML SUSPENSION has been published 36 times since Dec 17, 2025, and over the history we have for it it has declined 15.4%. The table below summarizes its recorded NADAC range and movement.

Current price$1.7482 per ML
All-time high$2.0669 (Feb 11, 2026)
All-time low$1.7482 (Aug 19, 2026)
52-week high$2.0669
52-week low$1.7482
Median price$1.9179
Average price$1.9199
Largest weekly change-4.0% (Apr 22, 2026)
Weeks tracked36
Tracking sinceDec 17, 2025

Price History

1W

-0.3%

1M

-0.3%

3M

-5.0%

6M

-13.9%

1Y

N/A

3Y

N/A

5Y

N/A

All

-15.4%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Rivaroxaban market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of RIVAROXABAN 1 MG/ML SUSPENSION?

The current National Average Drug Acquisition Cost (NADAC) for RIVAROXABAN 1 MG/ML SUSPENSION, manufactured by Ascend Laboratories, LLC, is $1.7482 per ML (NDC 67877088271), effective Aug 19, 2026.

How has the price of RIVAROXABAN 1 MG/ML SUSPENSION changed over time?

Over the history we have for it, the NADAC for RIVAROXABAN 1 MG/ML SUSPENSION has declined 15.4%. It has been tracked across 36 weekly CMS publications since Dec 17, 2025.

What are the highest and lowest recorded NADAC prices for RIVAROXABAN 1 MG/ML SUSPENSION?

Since Dec 17, 2025, the NADAC for RIVAROXABAN 1 MG/ML SUSPENSION has ranged from a low of $1.7482 (Aug 19, 2026) to a high of $2.0669 (Feb 11, 2026), with a median of $1.9179 per ML.

Are there cheaper alternatives to RIVAROXABAN 1 MG/ML SUSPENSION?

No other NADAC-published product currently shares the active ingredient and strength of RIVAROXABAN 1 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures RIVAROXABAN 1 MG/ML SUSPENSION?

RIVAROXABAN 1 MG/ML SUSPENSION (NDC 67877088271) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.